

Ref. No: 0769  
Date: 08/03/24  
Subject: Immunoglobulin Treatments

## REQUEST

1. In the past 3 months, how many patients have received the following treatments (for any disease):
  - Berinert (Human C1-esterase inhibitor)
  - Cinryze (Human C1-esterase inhibitor)
  - Firazyr (Icatibant)
  - Icatibant - any brand except Firazyr
  - Orladeyo (Berotralstat)
  - Ruconest (Recombinant human C1-esterase inhibitor)
  - Takhzyro (Lanadelumab)
  
2. In the past 3 months, how many patients have received the following immunoglobulin treatments (for any disease):
  - Cutaquig
  - Cuvitru
  - Gammagard
  - Gammanorm
  - Hizentra
  - Hyqvia
  - Intratect
  - Iqymune
  - Kiovig
  - Privigen
  - Octagam
  - Panzyga
  - Subgam
  - Any other normal immunoglobulin

## RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1<sup>st</sup> July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

### 1. In the past 3 months, how many patients have received the following treatments (for any disease):

#### St Helens and Knowsley:

Treatment	No. Patients
Berinert (Human C1-esterase inhibitor)	*
Cinryze (Human C1-esterase inhibitor)	0
Firazyr (Icatibant)	0
Icatibant - any brand except Firazyr	0
Orladeyo (Berotralstat)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Takhzyro (Lanadelumab)	0
* No data – ward stock	

#### Southport and Ormskirk:

Treatment	No. Patients
Berinert (Human C1-esterase inhibitor)	<5
Cinryze (Human C1-esterase inhibitor)	0
Firazyr (Icatibant)	0
Icatibant - any brand except Firazyr	0
Orladeyo (Berotralstat)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Takhzyro (Lanadelumab)	0

#### Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

**2. In the past 3 months, how many patients have received the following immunoglobulin treatments (for any disease):**

St Helens and Knowsley:

<b>Treatment</b>	<b>No. Patients</b>
Cutaquig	0
Cuvitru	0
Gammagard	0
Gammanorm	0
Hizentra	0
Hyqvia	0
Intratect	<5
Iqymune	0
Kiovig	0
Privigen	0
Octagam	8
Panzyga	0
Subgam	0
Any other normal immunoglobulin	0

Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.

Southport and Ormskirk:

<b>Treatment</b>	<b>No. Patients</b>
Cutaquig	0
Cuvitru	0
Gammagard	0
Gammanorm	0
Hizentra	0
Hyqvia	0
Intratect	10
Iqymune	0
Kiovig	0
Privigen	0
Octagam	0
Panzyga	0
Subgam	0
Any other normal immunoglobulin	0